(secondQuint)DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma.

 Multicenter, open-label, Phase 2 study.

 Subjects were randomized to either the investigational product, DN24-02, or to standard of care.

 Subjects randomized to the experimental arm received DN24-02 at 2-week intervals, for a total of 3 infusions.

 The study evaluated survival, disease-free survival, safety and the magnitude of the immune response between these 2 subject groups.

.

 DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma@highlight

This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.

